Clinical trials: Type1 Diabetes
Diabetes Mellitus, Type 1, Prediabetic State
Prevention Trial: Immune-tolerance With Alum-GAD (Diamyd) and Vitamin D3 to Children With Multiple Islet Autoantibodies
The purpose of this study is to evaluate if immune-tolerance with Alum-formulated GAD (Diamyd), in combination with high dose Vitamin D3, may delay or stop the autoimmune process leading to clinical type 1 diabetes in…
- Trial name
- DiAPREV-IT2 (NCT02387164)
- Testing
- Alum-GAD, Vitamin D3
- Where
- Sweden
- Volunteers
- 26 people
- Sponsor
- Lund University
Diabetes Mellitus, Type 1
A Study of LY2605541 (Insulin Peglispro) and Human Insulin Concentrations in Fat Tissue
LY2605541 is an investigational drug being developed for the treatment of diabetes mellitus. This study is designed to understand how the body handles the investigational drug, and to measure the quantity of LY2605541 in fat…
- Trial name
- NCT02109029
- Testing
- Insulin Peglispro, Human Insulin
- Where
- Austria
- Volunteers
- 24 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 1
A Study in Participants With Type I Diabetes Mellitus
The purpose of this study is: To compare blood sugar control on LY2605541 with insulin glargine after 52 weeks of treatment. To compare the rate of nocturnal low blood sugar episodes on LY2605541 with insulin glargine during 52…
- Trial name
- IMAGINE 3 (NCT01454284)
- Testing
- Glargine, LY2605541, Insulin Lispro
- Where
- 119 sites in United States, Australia and 18 more
- Volunteers
- 1,114 people
- Sponsor
- Eli Lilly and Company
Type1 Diabetes
Hybrid Closed Loop Therapy and Verapamil for Beta Cell Preservation in New Onset Type 1 Diabetes
Randomized trial of youth aged 7-<18 years with newly diagnosed stage 3 type 1 diabetes (T1D) to assess the effect of both (1) near-normalization of glucose concentrations achieved through use of a hybrid closed loop (HCL) system…
- Trial name
- CLVer (NCT04233034)
- Testing
- HCL, verapamil 120mg tablet, non-HCL
- Where
- 6 sites in United States
- Volunteers
- 113 people
- Sponsor
- Jaeb Center for Health Research
Diabetes Mellitus, Type 1
Adaptive, Real-time, Intelligent System to Enhance Self-care of Chronic Disease
The Adaptive, Real-time, Intelligent System to Enhance Self-care of chronic diseases (ARISES) project will use type 1 diabetes (T1DM) as an exemplary case study to demonstrate safety, technical proof of concept and efficacy of a…
- Trial name
- ARISES (NCT03643692)
- Testing
- ARISES
- Where
- United Kingdom
- Volunteers
- 12 people
- Sponsor
- Imperial College London
Type 1 Diabetes, Type 2 Diabetes
Safety Study of Using Symlin Alongside Insulin in a Multiple Injection Port
The purpose of this study is to determine whether injecting Symlin and insulin through a multiple injection port is safe and effective.
- Trial name
- NCT00790699
- Testing
- I-PORT, standard injections
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Texas Diabetes & Endocrinology, P.A.
Type 1 Diabetes, Hypoglycemia Unawareness
A Randomized Double Blinded Study to Examine the Use of N-acetyl Cysteine for the Prevention and Treatment of HAAF in Patients With Type 1 Diabetes
This is a single center, double blind randomized cross over design trial that will compare the impact of N-acetyl cysteine (200 mg) vs.
- Trial name
- NAC for HAAF (NCT02206152)
- Testing
- N-acetyl cysteine
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Minnesota
Diabetes, Diabetes Mellitus, Type 1
Comparison of NN1250 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes
This trial is conducted in Asia, Europe, Japan and South America. The aim of the trial is to compare the efficacy, safety and tolerability of NN1250 (insulin degludec ([Deg]) with insulin detemir (IDet), both combined with…
- Trial name
- BEGIN™ (NCT01074268)
- Testing
- insulin degludec, insulin detemir, insulin aspart
- Where
- 69 sites in Argentina, Brazil and 6 more
- Volunteers
- 456 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes
DiaBetter Together for Young Adults With Type 1 Diabetes
DiaBetter Together is a strengths-based peer support intervention delivered to young adults (age 17-25) by trained Peer Mentors (age 20-35) during the transition between pediatric and adult diabetes care.
- Trial name
- DiaBetter (NCT04247620)
- Testing
- DiaBetter Together, Peer Mentor Delivery
- Where
- United States
- Volunteers
- 144 people
- Sponsor
- Baylor College of Medicine
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
ACCU-CHEK® Aviva Expert Study: Does Use of a Bolus Advisor Improve Glycemic Control in Patients Not Achieving Optimal Control Using Multiple Daily Injections (MDI)?
This clinical, prospective, randomized, multi-center study determined if the use of an insulin bolus advisor improves glycemic control as measured by a change in HbA1c in patients failing multiple daily injection/intensified…
- Trial name
- ABACUS (NCT01460446)
- Testing
- Aviva Expert blood glucose meter, Aviva Nano blood glucose meter
- Where
- 33 sites in Germany, United Kingdom
- Volunteers
- 218 people
- Sponsor
- Hoffmann-La Roche
Diabetes Mellitus, Diabetes Mellitus, Type 1
PRECISION Study: Multi-center Study of Performance of a Novel Implanted CGM System Using a Next Generation Transmitter and Algorithm
The purpose of this multi-center, prospective clinical study is to evaluate the performance of a novel, implanted Senseonics continuous glucose monitoring system (Senseonics CGM System) compared to Yellow Springs Instrument (YSI)…
- Conditions
- Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- PRECISION (NCT03251079)
- Testing
- Continuous glucose monitoring system
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Senseonics, Inc.
Diabetes Mellitus, Type 1
Registry of Use and Application of Sensor Augmented Pump (SAP) Therapy Under Daily Life Conditions
The purpose of this registry is to collect the real life data on Sensor Augmented pump (SAP) therapy usage in type 1 Diabetes mellitus (DM) patients treated with Medtronic Insulin pumps and continuous glucose monitoring systems…
- Trial name
- RANSuP (NCT01718522)
- Testing
- sensor augmented pump (SAP)
- Volunteers
- 75 people
- Sponsor
- Medtronic MiniMed, Inc.
Type 1 Diabetes, Type 2 Diabetes
Adult Accuracy Study of the Enlite 3 Glucose Sensor
The purpose of this study is to demonstrate the performance of the Enlite 3 Sensor over 168 hours (7 days) when inserted in the abdomen and used with the Guardian Mobile App and 640G Pump in subjects aged 14-75 years with type 1…
- Trial name
- E3 (NCT02246582)
- Testing
- Enlite 3, Guardian Mobile App, 640G Insulin Pump
- Where
- 6 sites in United States
- Volunteers
- 118 people
- Sponsor
- Medtronic MiniMed, Inc.
Type 1 Diabetes
Children's Mercy Teens With Type 1 Diabetes Will Participate in an Online Peer Support Group.
The goal of this observational study is to examine the impact of an online peer support group in Children's Mercy teens with Type 1 Diabetes.
- Trial name
- NCT06412146
- Testing
- Peer Support Group
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Children's Mercy Hospital Kansas City
Type 1 Diabetes Mellitus
Feasibility Study of a Modular Control to Range System in Type 1 Diabetes Mellitus
In this protocol the investigators plan to demonstrate the feasibility of a modular insulin management system based on continuous glucose monitoring and targeted towards the avoidance of hypoglycemic and prolonged hyperglycemic…
- Trial name
- MDB003 (NCT01418703)
- Testing
- Closed Loop Control (CLC), Open Loop
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- University of Virginia
Type 1 Diabetes Mellitus
Comparison of Glucose Values and Variability Between TOUJEO and TRESIBA During Continuous Glucose Monitoring in Type 1 Diabetes Patients
Primary Objective: To demonstrate the non-inferiority of insulin glargine 300 units per milliliter (U/ml) in comparison to insulin degludec 100 U/ml on glycemic control and variability in participants with diabetes mellitus.
- Trial name
- inRange (NCT04075513)
- Testing
- Insulin glargine, 300 U/ml, Insulin degludec, 100U/ml, Background therapy: Rapid acting insulin analogs
- Where
- 7 sites in United States, Brazil and 5 more
- Volunteers
- 343 people
- Sponsor
- Sanofi
Type 1 Diabetes
"MyPlan" - Individualized Planned Eating Patterns for Adolescents With Type 1 Diabetes
The purpose of this study is to test the acceptability and effectiveness of an individualized eating strategy as part of diabetes self-management to improve glycemic levels among youth with type 1 diabetes (T1D) and suboptimal…
- Trial name
- NCT05147324
- Testing
- "MyPlan" - Individualized Planned Eating Pattern
- Where
- 2 sites in United States
- Volunteers
- 52 people
- Sponsor
- University of North Carolina, Chapel Hill
Prediabetes, Type 1 Diabetes
Diabetes Prevention - Immune Tolerance
A double-blind, randomized investigator-initiated study to determine the safety and the effect of Diamyd® on the progression to type 1 diabetes in children with multiple islet cell autoantibodies Eligible children are 4 years or…
- Trial name
- DIAPREV-IT (NCT01122446)
- Testing
- Diamyd
- Where
- Sweden
- Volunteers
- 50 people
- Sponsor
- Lund University
Diabetes Mellitus, Type 1
A Study of LY900014 in Elderly and Younger Adult Participants With Type 1 Diabetes Mellitus
The purpose of this study is to compare LY900014 with insulin lispro (Humalog) in elderly and younger adults with type 1 diabetes mellitus. Screening is required within 28 days prior to the start of the study.
- Trial name
- NCT03166124
- Testing
- LY900014, Insulin Lispro
- Where
- 2 sites in Germany
- Volunteers
- 80 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 1
A Study in Participants With Type 1 Diabetes Mellitus
The purpose of this study is: To compare the blood sugar control of LY2605541 with insulin glargine after 78 weeks of treatment.
- Trial name
- IMAGINE 1 (NCT01481779)
- Testing
- Glargine, LY2605541, Insulin Lispro
- Where
- 51 sites in United States, Austria and 7 more
- Volunteers
- 455 people
- Sponsor
- Eli Lilly and Company